Download pdf
Clinical application and future development trend of mRNA nanomedicine
- 1 College of Chemistry and Chemical Engineering, Inner Mongolia University, Inner Mongolia Autonomous Region, China
* Author to whom correspondence should be addressed.
Abstract
mRNA therapy is an emerging clinical therapeutic approach. According to studies, mRNA technology has entered into a stage of rapid development, and there are several significant achievements about some illness cancer such as cancer treatment, with various of mRNA nano-medicine have shown some promising results in clinical research. In recent years, with the deepening of research, mRNA nano-medicine shows the excellent potential in the prevention and treatment of diseases. 2020, with the first mRNA vaccines, which have been used for the treatment of the novel coronavirus, mRNA technology become the main focus of medical attention in the last decade. Based on the literature about mRNA in past five years and reference to the data and results of several clinical trials, this article adopts an approach of summary overview reviewing clinical applications of mRNA nano-medicine and predicting the tendency of future development. In the future, mRNA nanotechnology will become the mainstream method of diseases treatment, and bring hope to more patients. In this paper, we conduct a comprehensive description of mRNA nano-medicine from the following aspects: history and action mechanism, clinical application, current research status and future development trend.
Keywords
mRNA therapy, mRNA nano-medicine, diseases treatment, clinical application
[1]. Huang, X. , Kong, N. , Zhang, X. , Cao, Y. , Langer, R. , & Tao, W. . (2022). The landscape of mrna nanomedicine. Nature Medicine, 28.
[2]. Xiao, Z. Y., Wu, X. M., Guan, F., Zeng, C. Y., Xiong, W., & Wang, F. Y.. (2023). Mrna vaccine: an important breakthrough in defeating novel coronavirus infections. Advances in Biochemistry and Biophysics, 50.
[3]. Song, X. Q., Yi, Chao-Hui, M. Zhang, W. Y. Zhang, & Y. Y. Wang. (2024). Interpretation of the 2023 Nobel Prize in Physiology and Medicine - nucleoside base modification and mrna vaccines. Journal of Xinyang Normal University (Natural Science Edition) ,7.
[4]. Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018). Biomedical applications of mRNA nanomedicine. Nano research, 11.
[5]. Cao, J., Wei, Z., Nie, Y., & Chen, H. Z. (2024). Therapeutic potential of alternative splicing in cardiovascular diseases. Ebiomedicine, 101.
[6]. Tan, T., Deng, S. T., Wu, B. H., Yang, Q., Wu, M. W., Wu, H., ... & Xu, C. (2023). mRNA vaccine-A new cancer treatment strategy. Current cancer drug targets, 23.
[7]. Hu, C., Liu, J., Cheng, F., Bai, Y., Mao, Q., Xu, M., & Liang, Z. (2023). Amplifying mRNA vaccines: potential versatile magicians for oncotherapy. Frontiers in immunology, 14.
[8]. Li, M., Li, Y., Li, S., Jia, L., Wang, H., Li, M., ... & Zhu, T. (2022). The nano delivery systems and applications of mRNA. European journal of medicinal chemistry, 227.
[9]. Duan, Q., Hu, T., Zhu, Q., Jin X.,X., Chi, F., & Chen, X. (2022). How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development. Frontiers in Immunology, 13.
[10]. Peng, X., He, X., Zhang, W., Huang, H., Li, X., Chen, J., ... & Song, X. (2024). Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial. Journal of clinical oncology, 139.
Cite this article
Ren,J. (2024). Clinical application and future development trend of mRNA nanomedicine. Theoretical and Natural Science,65,56-61.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2024 Workshop: Computational Proteomics in Drug Discovery and Development from Medicinal Plants
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).